Completed

Oral VEGFR-2 Tyrosine Kinase Inhibitor for Recurrent Small-Volume Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Data Collection

Who is being recruted

Abdominal Neoplasms+19

+ Urogenital Diseases

+ Genital Diseases

Over 18 Years
+9 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 2
Interventional
Study Start: October 2003
See protocol details

Summary

Principal SponsorPfizer
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: October 1, 2003

Actual date on which the first participant was enrolled.

This study focuses on evaluating the effectiveness of an oral medication, CP-547,632, in treating small-volume epithelial ovarian cancer, primary peritoneal serous cancer, or fallopian tube cancer. These cancers often persist or recur despite initial treatment with platinum-based therapy. The study aims to help patients whose CA-125 levels, a protein indicator for these cancers, continue to rise after the first line of treatment. The potential outcomes of this research could lead to improved treatment options for those facing these challenging conditions. During the study, participants receive CP-547,632, a tyrosine kinase inhibitor that targets VEGFR-2, a protein involved in cancer growth. The primary goal is to assess whether this drug leads to a significant response in patients, as defined by predetermined response criteria. If the study's first stage does not meet these response criteria, it will not proceed to the second stage. This ensures that the study moves forward only if the drug shows promise in managing the targeted cancers.

Official TitleA Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Recurrent Or Persistent Small-Volume Epithelial Ovarian Cancer, Primary Peritoneal Serous Cancer, Or Fallopian Tube Cancer
NCT00074867
Principal SponsorPfizer
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

29 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Female

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Abdominal NeoplasmsUrogenital DiseasesGenital DiseasesAdnexal DiseasesDigestive System DiseasesDigestive System NeoplasmsEndocrine System DiseasesEndocrine Gland NeoplasmsFallopian Tube DiseasesFallopian Tube NeoplasmsFemale Urogenital Diseases and Pregnancy ComplicationsGenital Diseases, FemaleGenital Neoplasms, FemaleGonadal DisordersNeoplasmsNeoplasms by SiteOvarian DiseasesOvarian NeoplasmsPeritoneal DiseasesPeritoneal NeoplasmsUrogenital NeoplasmsFemale Urogenital Diseases

Criteria

4 inclusion criteria required to participate
Histologically proven epithelial ovarian cancer, primary peritoneal serous cancer, or fallopian tube cancerRecurrent or persistent elevated CA-125.
For the purpose of this study, elevated CA-125 is defined as a value of ≥40 U/ml on two separate consecutive determinations made ≥1 week apart.
CA-125 values obtained within 4 weeks of abdominal surgery should not be taken into account.
No definitive disease or clinical and findings of small volume disease (£1cm by spiral CT or £2cm by conventional CT or clinical exam).
5 exclusion criteria prevent from participating
No prior exposure to mouse antibodies or prior VEGF or VEGF receptor targeted treatment or other anti-angiogenic-directed, anti-cancer treatment including thalidomide.
No prior consolidation therapy with cytotoxic agents for ovarian cancer.
No requirement for concomitant anticoagulant therapy.
Continuation of hormone replacement therapy is permitted.
Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Study Objectives

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 9 locations

Suspended

Pfizer Investigational Site

Los Angeles, United StatesOpen Pfizer Investigational Site in Google Maps
Suspended

Pfizer Investigational Site

Santa Monica, United States
Suspended

Pfizer Investigational Site

Baltimore, United States
Suspended

Pfizer Investigational Site

Boston, United States
Completed9 Study Centers